Astria Therapeutics Inc (ATXS) USD0.001
Astria Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients and families affected by rare and niche allergic and immunological diseases. Its lead product candidate, STAR-0215, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Plasma kallikrein is an enzyme that cleaves high molecular weight kininogen (HMWK), to release bradykinin. It has four therapies for on-demand treatment of HAE: BERINERT (C1 esterase inhibitor (human)), FIRAZYR (icatibant injection), KALBITOR (ecallantide) and RUCONEST (C1 esterase inhibitor (recombinant)). Its long-term preventative treatment of HAE therapies: CINRYZE (C1 esterase inhibitor (human)), HAEGARDA (C1 esterase inhibitor subcutaneous (human)), TAKHZYRO (lanadelumab-flyo) and ORLADEYO (berotralstat).
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.